Case Reports
doi: 10.1016/j.jocn.2005.09.008.
Epub 2006 Jun 30.
Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody
Affiliations
- PMID: 16814550
- DOI: 10.1016/j.jocn.2005.09.008
Item in Clipboard
Case Reports
Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody
J Clin Neurosci.
2006 Jul.
Abstract
We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.
Similar articles
-
Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus.J Neurol Sci. 2007 May 15;256(1-2):100-2. doi: 10.1016/j.jns.2007.02.027. Epub 2007 Mar 23. J Neurol Sci. 2007. PMID: 17382963
-
Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy.J Neurol Sci. 2004 Sep 15;224(1-2):29-35. doi: 10.1016/j.jns.2004.05.014. J Neurol Sci. 2004. PMID: 15450768 Clinical Trial.
-
Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy.Muscle Nerve. 2000 Jun;23(6):895-9. doi: 10.1002/(sici)1097-4598(200006)23:6<895::aid-mus8>3.0.co;2-g. Muscle Nerve. 2000. PMID: 10842265
-
Atypical chronic inflammatory demyelinating polyradiculoneuropathy with ophthalmoplegia and anti-sulfatide IgM positivity.J Int Med Res. 2023 Oct;51(10):3000605231193575. doi: 10.1177/03000605231193575. J Int Med Res. 2023. PMID: 37812511 Free PMC article. Review.
-
Childhood acute and chronic immune-mediated polyradiculoneuropathies.Eur J Paediatr Neurol. 2009 May;13(3):209-18. doi: 10.1016/j.ejpn.2008.04.009. Epub 2008 Jun 26. Eur J Paediatr Neurol. 2009. PMID: 18585069 Review.
Cited by
-
Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Curr Neuropharmacol. 2011 Sep;9(3):468-77. doi: 10.2174/157015911796557939. Curr Neuropharmacol. 2011. PMID: 22379461 Free PMC article.
-
Immune-mediated neuropathies.Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2. Nat Rev Dis Primers. 2018. PMID: 30310069 Review.
-
Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial.JMIR Res Protoc. 2020 Apr 1;9(4):e17117. doi: 10.2196/17117. JMIR Res Protoc. 2020. PMID: 32234705 Free PMC article.
-
Practical considerations on the use of rituximab in autoimmune neurological disorders.Ther Adv Neurol Disord. 2010 Mar;3(2):93-105. doi: 10.1177/1756285609356135. Ther Adv Neurol Disord. 2010. PMID: 21179602 Free PMC article.
-
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.Cochrane Database Syst Rev. 2016 Oct 4;10(10):CD002827. doi: 10.1002/14651858.CD002827.pub4. Cochrane Database Syst Rev. 2016. PMID: 27701752 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
